Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
Men and post- or induced menopausal women with ER\[+\] and/or PgR\[+\], HER2\[- \] advanced BC, with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.
Breast Cancer
DRUG: Alpelisib|DRUG: Metformin|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Exemestane|DRUG: Vildagliptin|DRUG: Tamoxifen
Assess the rate of patients with G3-4 hyperglycemia (HG) by CTCAE v4.03 over the first 2 cycles of treatment with alpelisib (BYL719) (Cohorts A and B), The primary objective is to assess the rate of patients with G3-4 (CTCAE v4.03) hyperglycemia (HG) over the first 2 cycles of treatment with alpelisib (BYL719) (300 mg/QD) plus endocrine therapy and metformin, in patients with normal fasting glycemia and HbA1c (cohort A), and in patients with high-risk criteria (cohort B)., Baseline up tp 15 months|Assess the rate of patients with permanent discontinuation of alpelisib due to related AEs after 8 weeks of treatment with alpelisib plus endocrine therapy and antidiabetic treatment (Cohort C)., The primary objective is to assess the rate of patients with permanent discontinuation of alpelisib due to related AEs after 8 weeks of treatment with alpelisib plus endocrine therapy and antidiabetic treatment in patients with insuline naive type 2 diabetic mellitus patients (cohort C)., Baseline up tp 15 months
Clinical efficacy of alpelisib plus endocrine therapy, and antidiabetic treatment will be exploratory evaluated based on CTCAE V4.03 guidelines, To evaluate the clinical efficacy -in terms of progression-free survival (PFS), overall response rate (ORR), time to response (TTR), duration of the response (DoR), time to progression (TTP), clinical benefit rate (CBR)- of combining alpelisib plus endocrine therapy, and antidiabetic treatment in patients with HR\[+\]/HER2\[-\], PIK3CAMut ABC in all study cohorts and according to the different endocrine agent received., Baseline up to 15 months|Progression free survival [PFS], Progression free survival \[PFS\] (defined as the time from the date of inclusion to the date of the first documented progression or death due to any cause, in the overall population, in all cohorts, and according to the different endocrine agent received. If a patient has not had an event, PFS will be censored at the date of the last adequate tumor evaluation \[see RECIST 1.1\])., Baseline up to 15 months|Overall response rate [ORR], Overall response rate \[ORR\] (defined as the proportion of patients with best overall response -including complete response \[CR\] or partial response \[PR\]- based on local investigator's assessment (RECIST 1.1), in the overall population, in all cohorts, and according to the different endocrine agent received., Baseline up to 15 months|Time to response [TTR], Time to response \[TTR\], defined as the period from the treatment initiation to time of the first objective tumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a CR or PR, as determined locally by the investigator through the use of RECIST v.1.1.· in all the cohorts, and according to the different endocrine agent received)., Baseline up to 15 months|Duration of the response [DoR], The period from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, as determined locally by the investigator through use of RECIST v.1.1. in all the cohorts, and according to the different endocrine agent received., Baseline up to 15 months|Time to progression [TTP], Time to progression \[TTP\] (defined as the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to underlying cancer, in the overall population, in all cohorts, and according to the different endocrine agent received. If a patient has not had an event, time to progression is censored at the date of last adequate tumor assessment)., Baseline up to 15 months|Clinical benefit rate [CBR], Clinical benefit rate \[CBR\] (defined as the proportion of patients with a best overall response of CR or PR or SD or Non-CR/Non-PD lasting more than 24 weeks based on local investigator assessment), in the overall population, in all cohorts, and according to the different endocrine agent received., Baseline up to 15 months|Rate of any grade and grade 3-4 HG by CTCAE v.4.03 in Cohorts A, B, and C, To assess the rate of any grade and grade 3-4 HG by CTCAE v.4.03 in cohorts A, B, and C for Metallica and its comparation with Solar-1, and Bylieve trials., Baseline up to 15 months|Rate of patients with permanent treatment discontinuation at 8 weeks, To assess the rate of patients with permanent treatment discontinuation at 8 weeks of treatment with alpelisib due to treatment-related AEs in patients with normal fasting glycemia and HbA1c (Cohort A), and in patients with impaired fasting glucose criteria (Cohort B)., Baseline up to 15 months|Rate of patients with permanent treatment discontinuation in all cohorts, To assess the rate of patients with permanent discontinuation due to alpelisib treatment-related AEs in Cohorts A, B, and C for Metallica, and to compare it with SOLAR-1, and Bylieve trials., Baseline up to 15 months|Rate of patients with permanent treatment discontinuation antidiabetic treatment), due to related AEs in all patients and all study cohorts, To assess the rate of patients with alpelisib permanent discontinuation due to related AEs over the first 8 weeks in the overall population, in all and according to the different endocrine agent received., Baseline up to 15 months|Rate of patients with grade 3-4 HG as per CTCAE v.4.03 over the first 8 weeks of treatment with alpelisib plus endocrine therapy and antidiabetic treatment and during the whole study, To assess the rate of patients with grade 3-4 HG as per CTCAE v.4.03 over the first 8 weeks of treatment with alpelisib plus endocrine therapy and antidiabetic treatment and during the whole study, in all study cohorts, according to the different endocrine agent received., Baseline up to 15 months|Rate of patients that requires insulin to control HG during the first 8 weeks and throughout study, To assess the rate of patients that requires insulin to control HG during over the first 8 weeks of treatment with alpelisib plus endocrine therapy and antidiabetic treatment and during the whole study, in all study cohorts, according to the different endocrine agent received.

The number and class of antidiabetic agents used during the first 8 weeks and throughout study, in the overall population, in all the cohorts., Baseline up to 15 months|Type of HG in patients with grade 3-4 HG as per CTCAE v.4.03 and 5.0, To define the type of HG in patients with grade 3-4 HG as per CTCAE v.4.03 and 5.0 in all the study cohorts and according to the different endocrine agent received, and the rate of patients with HG all the cohorts and according to the different endocrine agent received as per CTCAE v.4.03 and as per CTCAE v.5., Baseline up to 15 months|The rate of any grade and grade 3-4 diarrhea by CTCAE v.4.03, To assess the rate of any grade and grade 3-4 diarrhea by CTCAE v.4.03 for Metallica., Baseline up to 15 months|Safety and tolerability of the combination of alpelisib with endocrine therapy, and antidiabetic treatment, To evaluate the safety and tolerability of the combination of alpelisib with endocrine therapy, and antidiabetic treatment in all study cohorts and according to the different endocrine agent received., Baseline up to 15 months|AEs according to the different endocrine agent received as per CTCAE v.4.03, To define the rate of patients with grade 3-4 AEs as per CTCAE v.4.03 in all study cohorts and according to the different endocrine agent received., Baseline up to 15 months
Men and post- or induced menopausal women with ER\[+\] and/or PgR\[+\], HER2\[- \] advanced BC, with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.Men and post- or induced menopausal women with ER\[+\] and/or PgR\[+\], HER2\[- \] advanced BC, with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.Measurable or evaluable disease according to RECIST v.1.1 criteria.No prior treatment with fulvestrant or PI3K, AKT or mTOR inhibitors.

No more than one prior line of chemotherapy for metastatic breast cancer (MBC). Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 1. Non-diabetic patients will be assigned to Cohorts A or B and insulin naïve patients with established diagnosis of type 2 diabetes mellitus will be assigned to Cohort C.